Clinical utility of gene expression profiling data for clinical decision-making regarding adjuvant therapy in early stage, node-negative breast cancer: A case report

Steven R. Schuster, Barbara A Pockaj, Mary R. Bothe, Paru S. David, Donald W Northfelt

Research output: Contribution to journalArticle

Abstract

Breast cancer is the most common malignancy among women in the United States with the second highest incidence of cancer-related death following lung cancer. The decision-making process regarding adjuvant therapy is a time intensive dialogue between the patient and her oncologist. There are multiple tools that help individualize the treatment options for a patient. Population-based analysis with Adjuvant! Online and genomic profiling with Oncotype DX are two commonly used tools in patients with early stage, node-negative breast cancer. This case report illustrates a situation in which the population-based prognostic and predictive information differed dramatically from that obtained from genomic profiling and affected the patient's decision. In light of this case, we discuss the benefits and limitations of these tools.

Original languageEnglish (US)
Pages (from-to)71-76
Number of pages6
JournalJournal of Personalized Medicine
Volume2
Issue number3
DOIs
StatePublished - Jan 1 2012

Fingerprint

Gene Expression Profiling
Breast Neoplasms
Therapeutics
Population
Lung Neoplasms
Neoplasms
Decision Making
Clinical Decision-Making
Incidence

Keywords

  • Breast cancer
  • Chemotherapy
  • Genomic profiling
  • Medical decision-making
  • Oncotype DX
  • Personalized medicine

ASJC Scopus subject areas

  • Medicine (miscellaneous)

Cite this

@article{12b3f7dfe30d48349fe05ec39ec32692,
title = "Clinical utility of gene expression profiling data for clinical decision-making regarding adjuvant therapy in early stage, node-negative breast cancer: A case report",
abstract = "Breast cancer is the most common malignancy among women in the United States with the second highest incidence of cancer-related death following lung cancer. The decision-making process regarding adjuvant therapy is a time intensive dialogue between the patient and her oncologist. There are multiple tools that help individualize the treatment options for a patient. Population-based analysis with Adjuvant! Online and genomic profiling with Oncotype DX are two commonly used tools in patients with early stage, node-negative breast cancer. This case report illustrates a situation in which the population-based prognostic and predictive information differed dramatically from that obtained from genomic profiling and affected the patient's decision. In light of this case, we discuss the benefits and limitations of these tools.",
keywords = "Breast cancer, Chemotherapy, Genomic profiling, Medical decision-making, Oncotype DX, Personalized medicine",
author = "Schuster, {Steven R.} and Pockaj, {Barbara A} and Bothe, {Mary R.} and David, {Paru S.} and Northfelt, {Donald W}",
year = "2012",
month = "1",
day = "1",
doi = "10.3390/jpm2030071",
language = "English (US)",
volume = "2",
pages = "71--76",
journal = "Journal of Personalized Medicine",
issn = "2075-4426",
publisher = "Multidisciplinary Digital Publishing Institute (MDPI)",
number = "3",

}

TY - JOUR

T1 - Clinical utility of gene expression profiling data for clinical decision-making regarding adjuvant therapy in early stage, node-negative breast cancer

T2 - A case report

AU - Schuster, Steven R.

AU - Pockaj, Barbara A

AU - Bothe, Mary R.

AU - David, Paru S.

AU - Northfelt, Donald W

PY - 2012/1/1

Y1 - 2012/1/1

N2 - Breast cancer is the most common malignancy among women in the United States with the second highest incidence of cancer-related death following lung cancer. The decision-making process regarding adjuvant therapy is a time intensive dialogue between the patient and her oncologist. There are multiple tools that help individualize the treatment options for a patient. Population-based analysis with Adjuvant! Online and genomic profiling with Oncotype DX are two commonly used tools in patients with early stage, node-negative breast cancer. This case report illustrates a situation in which the population-based prognostic and predictive information differed dramatically from that obtained from genomic profiling and affected the patient's decision. In light of this case, we discuss the benefits and limitations of these tools.

AB - Breast cancer is the most common malignancy among women in the United States with the second highest incidence of cancer-related death following lung cancer. The decision-making process regarding adjuvant therapy is a time intensive dialogue between the patient and her oncologist. There are multiple tools that help individualize the treatment options for a patient. Population-based analysis with Adjuvant! Online and genomic profiling with Oncotype DX are two commonly used tools in patients with early stage, node-negative breast cancer. This case report illustrates a situation in which the population-based prognostic and predictive information differed dramatically from that obtained from genomic profiling and affected the patient's decision. In light of this case, we discuss the benefits and limitations of these tools.

KW - Breast cancer

KW - Chemotherapy

KW - Genomic profiling

KW - Medical decision-making

KW - Oncotype DX

KW - Personalized medicine

UR - http://www.scopus.com/inward/record.url?scp=85041157441&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85041157441&partnerID=8YFLogxK

U2 - 10.3390/jpm2030071

DO - 10.3390/jpm2030071

M3 - Article

AN - SCOPUS:85041157441

VL - 2

SP - 71

EP - 76

JO - Journal of Personalized Medicine

JF - Journal of Personalized Medicine

SN - 2075-4426

IS - 3

ER -